The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers

Oncogene

Volumn 29, Issue 34, 2010, Pages 4838-4847

  Hrstka, R ^a   Nenutil, R ^a   Fourtouna, A ^b   Maslon, M M ^b   Naughton, C ^b   Langdon, S ^b   Murray, E ^b   Larionov, A ^c   Petrakova, K ^a   Muller, P ^a   Dixon, M J ^c   Hupp, T R ^b   Vojtesek, B ^a  

^a MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

AGR2; breast cancer; estrogen receptor; letrozole; tamoxifen

Indexed keywords

ANTERIOR GRADIENT 2 PROTEIN; ESTROGEN RECEPTOR ALPHA; LETROZOLE; ONCOPROTEIN; TAMOXIFEN; UNCLASSIFIED DRUG; AGR2 PROTEIN, HUMAN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PREVENTION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REPORTER GENE; TREATMENT RESPONSE; BREAST NEOPLASMS; DRUG EFFECTS; FEMALE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; PROGNOSIS; PROTEINS; TAMOXIFEN; TRANSFECTION;

EID: 77956170869     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.228     Document Type: Article

References (43)

1. 4838-4847Aberger F, Weidinger G, Grunz H, Richter K. (1998). Anteriorspecification of embryonic ectoderm: the role of the Xenopuscement gland-specific gene XAG-2. Mech Dev 72: 115-130.
2. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson Let al. (2003). Comprehensive proteomic analysis of breast cancer cellmembranes reveals unique proteins with potential roles in clinicalcancer. J Biol Chem 278: 6482-6489.
3. Anderson I, Gorski J. (2000). Estrogen receptor alpha interaction withestrogen response element half-sites from the rat prolactin gene.Biochemistry 39: 3842-3847.
4. Barraclough DL, Platt-Higgins A, de Silva Rudland S, Barraclough R,Winstanley J, West CR et al. (2009). The metastasis-associatedanterior gradient 2 protein is correlated with poor survival of breastcancer patients. Am J Pathol 175: 1848-1857.
5. Barraclough DL, Sewart S, Rudland PS, Shoker BS, Sibson DR,Barraclough R et al. (2010). Microarray analysis of suppressionsubtracted hybridisation libraries identifies genes associated withbreast cancer progression. Cell Oncol 32: 87-99.
6. Brunner N, Boysen B, Jirus S, Skaar TC, Holst-Hansen C, Lippman Jet al. (1997). MCF7/LCC9: an antiestrogen-resistant MCF-7 variantin which acquired resistance to the steroidal antiestrogen ICI182,780 confers an early cross-resistance to the nonsteroidalantiestrogen tamoxifen. Cancer Res 57: 3486-3493.
7. Coser KR, Wittner BS, Rosenthal NF, Collins SC, Melas A, Smith SLet al. (2009). Antiestrogen-resistant subclones of MCF-7 humanbreast cancer cells are derived from a common monoclonal drugresistantprogenitor. Proc Natl Acad Sci USA 106: 14536-14541.
8. Fletcher GC, Patel S, Tyson K, Adam PJ, Schenker M, Loader JAet al. (2003). hAG-2 and hAG-3, human homologues of genesinvolved in differentiation, are associated with oestrogen receptorpositivebreast tumours and interact with metastasis gene C4.4a anddystroglycan. Br J Cancer 88: 579-585.
9. Fritzsche FR, Dahl E, Pahl S, Burkhardt M, Luo J, Mayordomo Eet al. (2006). Prognostic relevance of AGR2 expression in breastcancer. Clin Cancer Res 12: 1728-1734.
10. Goetz MP, Loprinzi CL. (2003). A hot flash on tamoxifen metabolism.J Natl Cancer Inst 95: 1734-1735.
11. Gruber CJ, Gruber DM, Gruber IM, Wieser F, Huber JC. (2004).Anatomy of the estrogen response element. Trends EndocrinolMetab 15: 73-78.
12. Gunthert AR, Grundker C, Olota A, Lasche J, Eicke N, Emons G.(2005). Analogs of GnRH-I and GnRH-II inhibit epidermal growthfactor-induced signal transduction and resensitize resistant humanbreast cancer cells to 4OH-tamoxifen. Eur J Endocrinol 153: 613-625.
13. Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van HeekNT, Rosty C et al. (2003). Exploration of global gene expressionpatterns in pancreatic adenocarcinoma using cDNA microarrays.Am J Pathol 162: 1151-1162.
14. Innes HE, Liu D, Barraclough R, Davies MP, O'Neill PA, Platt-Higgins A et al. (2006). Significance of the metastasis-inducingprotein AGR2 for outcome in hormonally treated breast cancerpatients. Br J Cancer 94: 1057-1065.
15. Jacquemier JD, Hassoun J, Torrente M, Martin PM. (1990).Distribution of estrogen and progesterone receptors in healthytissue adjacent to breast lesions at various stages\immunohistochemicalstudy of 107 cases. Breast Cancer Res Treat 15: 109-117.
16. Johnston SR. (1997). Acquired tamoxifen resistance in human breastcancer-potential mechanisms and clinical implications. AnticancerDrugs 8: 911-930.
17. Katzenellenbogen BS, Frasor J. (2004). Therapeutic targeting in theestrogen receptor hormonal pathway. Semin Oncol 31: 28-38.
18. Kim NS, Shen YN, Kim TY, Byun SJ, Jeon IS, Kim SH. (2007).Expression of AGR-2 in chicken oviduct during laying period.J Biochem Mol Biol 40: 212-217.
19. Knowlden JM, Hutcheson IR, Barrow D, Gee JM, Nicholson RI.(2005). Insulin-like growth factor-I receptor signaling in tamoxifenresistantbreast cancer: a supporting role to the epidermal growthfactor receptor. Endocrinology 146: 4609-4618.
20. Kondrakhin YV, Sharipov RN, Keld AE, Kolpakov FA. (2008).Identification of differentially expressed genes by meta-analysis ofmicroarray data on breast cancer. In Silico Biol 8: 383-411.
21. Kumar A, Godwin JW, Gates PB, Garza-Garcia AA, Brockes JP.(2007). Molecular basis for the nerve dependence of limb regenerationin an adult vertebrate. Science 318: 772-777.
22. Kumar V, Green S, Stack G, Berry M, Jin Jr., Chambon P. (1987).Functional domains of the human estrogen receptor. Cell 51:941-951.
23. Lee S, Bang S, Song K, Lee I. (2006). Differential expression innormal-adenoma-carcinoma sequence suggests complex molecularcarcinogenesis in colon. Oncol Rep 16: 747-754.
24. Liu D, Rudland PS, Sibson DR, Platt-Higgins A, Barraclough R.(2005). Human homologue of cement gland protein, a novelmetastasis inducer associated with breast carcinomas. Cancer Res65: 3796-3805.
25. Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K,Ashworth A et al. (2007). Molecular response to aromataseinhibitor treatment in primary breast cancer. Breast Cancer Res 9:R37.
26. Metzger D, Ali S, Bornert JM, Chambon P. (1995). Characterizationof the amino-terminal transcriptional activation function of thehuman estrogen receptor in animal and yeast cells. J Biol Chem 270:9535-9542.
27. Normanno N, Di Maio M, De Maio E, De Luca A, de Matteis A,Giordano A et al. (2005). Mechanisms of endocrine resistance andnovel therapeutic strategies in breast cancer. Endocr Relat Cancer12: 721-747.
28. Osborne CK, Schiff R. (2005). Estrogen-receptor biology: continuingprogress and therapeutic implications. J Clin Oncol 23: 1616-1622.
29. Petek E, Windpassinger C, Egger H, Kroisel PM, Wagner K. (2000).Localization of the human anterior gradient-2 gene (AGR2) tochromosome band 7p21.3 by radiation hybrid mapping andfluorescence in situ hybridisation. Cytogenet Cell Genet 89: 141-142.
30. Pohler E, Craig AL, Cotton J, Lawrie L, Dillon JF, Ross P et al.(2004). The Barrett's antigen anterior gradient-2 silences the p53transcriptional response to DNA damage. Mol Cell Proteomics 3:534-547.
31. Ramachandran V, Arumugam T, Wang H, Logsdon CD. (2008).Anterior gradient 2 is expressed and secreted during the developmentof pancreatic cancer and promotes cancer cell survival. CancerRes 68: 7811-7818.
32. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. (2007).Pathways to tamoxifen resistance. Cancer Lett 256: 1-24.
33. Robertson JF, Cannon PM, Nicholson RI, Blamey RW. (1996).Oestrogen and progesterone receptors as prognostic variables inhormonally treated breast cancer. Int J Biol Markers 11: 29-35.
34. Smirnov DA, Zweitzig DR, Foulk BW, Miller MC, Doyle GV, PientaKJ et al. (2005). Global gene expression profiling of circulatingtumor cells. Cancer Res 65: 4993-4997.
35. Stendahl M, Kronblad A, Ryden L, Emdin S, Bengtsson NO,Landberg G. (2004). Cyclin D1 overexpression is a negativepredictive factor for tamoxifen response in postmenopausal breastcancer patients. Br J Cancer 90: 1942-1948.
36. Thompson DA, Weigel RJ. (1998). hAG-2, the human homologue ofthe Xenopus laevis cement gland gene XAG-2, is coexpressed withestrogen receptor in breast cancer cell lines. Biochem Biophys ResCommun 251: 111-116.
37. Tyulmenkov VV, Klinge CM. (2001). A mathematical approach topredict the affinity of estrogen receptors alpha and beta binding toDNA. Mol Cell Endocrinol 182: 109-119.
38. Tzukerman MT, Esty A, Santiso-Mere D, Danielian P,Parker MG, Stein RB et al. (1994). Human estrogenreceptor transactivational capacity is determined by bothcellular and promoter context and mediated by two functionallydistinct intramolecular regions. Mol Endocrinol 8:21-30.
39. Wang Z, Hao Y, Lowe AW. (2008). The adenocarcinoma-associatedantigen, AGR2, promotes tumor growth, cell migration, andcellular transformation. Cancer Res 68: 492-497.
40. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PSet al. (2007). Increased expression of anterior gradient-2 issignificantly associated with poor survival of prostate cancerpatients. Prostrate Cancer Prostatic Dis 10: 293-300.
41. Zheng W, Rosenstiel P, Huse K, Sina C, Valentonyte R, Mah N et al.(2006). Evaluation of AGR2 and AGR3 as candidate genes forinflammatory bowel disease. Genes Immun 7: 11-18.
42. Zhu H, Lam DC, Han KC, Tin VP, Suen WS, Wang E et al. (2007).High resolution analysis of genomic aberrations by metaphase andarray comparative genomic hybridization identifies candidatetumour genes in lung cancer cell lines. Cancer Lett 245: 303-314.
43. Zweitzig DR, Smirnov DA, Connelly MC, Terstappen LW, O'Hara SM,Moran E. (2007). Physiological stress induces the metastasis markerAGR2 in breast cancer cells.Mol Cell Biochem 306: 255-260.